Xiao Xu

Xiao Xu

Auto-generated profile, based on publicly available information

Xiao Xu

Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in ACS Nano
Verified
Journal Article
Open access
XXXiao Xu
Xiao Xu
Xiang WangXiang Wang
Xiang Wang
YLYu-Pei Liao
Yu-Pei Liao
LLLijia Luo
Lijia Luo
Tian XiaTian Xia
Tian Xia
ANAndre Nel
Andre Nel
While oral desensitization is capable of alleviating peanut allergen anaphylaxis, long-term immune tolerance is the sought-after goal. We developed a liver-targeting lipid nanoparticle (LNP) platform to deliver mRNA-encoded peanut allergen epitopes to liver sinusoidal endothelial cells (LSECs), which function as robust tolerogenic antigen-presenting cells that induce FoxP3+ regulatory T-cells (Tregs). The mRNA strand was constructed by including nucleotide sequences encoding for nonallergenic MHC-II binding T-cell epitopes, identified in the dominant peanut allergen, Ara h2. These epitopes were inserted in the mRNA strand downstream of an MHC-II targeting sequence, further endowed in vitro with 5' and 3' capping sequences, a PolyA tail, and uridine substitution. Codon-optimized mRNA was used for microfluidics synthesis of LNPs with an ionizable cationic lipid, also decorated with a lipid-anchored mannose ligand for LSEC targeting. Biodistribution to the liver was confirmed by in vivo imaging, while ELISpot assays demonstrated an increase in IL-10-producing Tregs in the spleen. Prophylactic administration of tandem-repeat or a combination of encapsulated Ara h2 epitopes induced robust tolerogenic effects in C3H/HeJ mice, sensitized to and subsequently challenged with crude peanut allergen extract. In addition to alleviating physical manifestations of anaphylaxis, there was suppression of Th2-mediated cytokine production, IgE synthesis, and mast cell release, accompanied by increased IL-10 and TGF-β production in the peritoneum. Similar efficacy was demonstrated during LNP administration postsensitization. While nondecorated particles had lesser but significant effects, PolyA/LNP-Man lacked protective effects. These results demonstrate an exciting application of mRNA/LNP for treatment of food allergen anaphylaxis, with the promise to be widely applicable to the allergy field.

30 March 2023 in ACS Nanoscience Au
Verified
Journal Article
Open access
XXXiao Xu
Xiao Xu
Tian XiaTian Xia
Tian Xia
The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a template for protein synthesis in the ribosome. Despite its utility, the instability of mRNA requires suitable carriers for in vivo delivery. Lipid nanoparticles (LNPs) are employed to protect mRNA from degradation and enhance its intracellular delivery. To further optimize the therapeutic efficacy of mRNA, site-specific LNPs have been developed. Through local or systemic administration, these site-specific LNPs can accumulate in specific organs, tissues, or cells, allowing for the intracellular delivery of mRNA to specific cells and enabling the exertion of local or systemic therapeutic effects. This not only improves the efficiency of mRNA therapy but also reduces off-target adverse effects. In this review, we summarize recent site-specific mRNA delivery strategies, including different organ- or tissue-specific LNP after local injection, and organ-specific or cell-specific LNP after intravenous injection. We also provide an outlook on the prospects of mRNA therapy.

9 October 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
XXXiao Xu
Xiao Xu
XHXuechao Huang
Xuechao Huang
YZYing Zhang
Ying Zhang
SSShiyang Shen
Shiyang Shen
ZFZhizi Feng
Zhizi Feng
RMRan Mo
Ran Mo
Polymeric nanogel with on-demand release of hirudin prevents and inhibits clot formation.

3 March 2025 in ACS Nano
Verified
Journal Article
Open access
XXXiao Xu
Xiao Xu
Xiang WangXiang Wang
Xiang Wang
YLYu-Pei Liao
Yu-Pei Liao
LLLijia Luo
Lijia Luo
ANAndre Nel
Andre Nel
We demonstrate reprogramming of the tolerogenic immune environment in the liver for mounting an effective immune response against often-fatal pancreatic cancer metastases. This was achieved by engineering a lipid nanoparticle (LNP) to deliver mRNA encoding the KRAS G12D neoantigenic epitope along with cGAMP, a dinucleotide agonist of the stimulator of the interferon genes (STING) pathway, capable of activating a type I interferon response. cGAMP/mKRAS/LNP were synthesized by a microfluidics approach involving nanoprecipitation of mRNA and cGAMP by an ionizable lipid, MC3. Controls included nanoparticles delivering individual components or a wild-type RAS sequence. The dual delivery carrier successfully activated the type I interferon pathway in vitro as well as in vivo, with reprogramming of costimulatory receptor (CD80 and CD86) and MHC-I expression on liver antigen-presenting cells (APC). This allowed the generation of IFN-γ producing cytotoxic T cells, capable of mounting an effective immune response in the metastatic KRAS pancreatic cancer (KPC) mouse model. Noteworthy, intravenous injection of cGAMP/mKRAS/LNP suppressed metastatic growth significantly and prolonged animal survival, both prophylactically and during treatment of established metastases. The protective immune response was mediated by the generation of perforin-releasing CD8+ cytotoxic T cells, engaged in pancreatic cancer cell killing. Importantly, the immune response could also be adoptively transferred by injecting splenocytes (containing memory T cells) from treated into nontreated recipient mice. This study demonstrates that reprogramming the immune-protective niche for metastatic pancreatic cancer can be achieved by the delivery of a STING agonist and mutant KRAS mRNA via ionizable LNPs, offering both prophylactic and therapeutic advantages.